Systematic Verification of Bladder Cancer-associated Tissue Protein Biomarker Candidates in Clinical Urine Specimens

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Aug 17

PMID 30112103

Citations 10

Authors

Cheng-Han Tsai

Yi-Ting Chen

Ying-Hsu Chang

Chuen Hsueh

Chung-Yi Liu

Yu-Sun Chang

Chien-Lun Chen

Jau-Song Yu

Affiliations

Soon will be listed here.

Abstract

Bladder cancer biomarkers currently approved by the Food and Drug Administration are insufficiently reliable for use in non-invasive clinical diagnosis. Verification/validation of numerous biomarker candidates for BC detection is a crucial bottleneck for novel biomarker development. A multiplexed liquid chromatography multiple-reaction-monitoring mass spectrometry assay of 122 proteins, including 118 up-regulated tissue proteins, two known bladder cancer biomarkers and two housekeeping gene products, was successfully established for protein quantification in clinical urine specimens. Quantification of 122 proteins was performed on a large cohort of urine specimens representing a variety of conditions, including 142 hernia, 126 bladder cancer, 67 hematuria, and 59 urinary tract infection samples. ANXA3 (annexin A3) and HSPE1 (heat shock protein family E member 1), which showed the highest detection frequency in bladder cancer samples, were selected for further validation. Western blotting showed that urinary ANXA3 and HSPE1 protein levels were higher in bladder cancer samples than in hernia samples, and enzyme-linked immunosorbent assays confirmed a higher urinary concentration of HSPE1 in bladder cancer than in hernia, hematuria and urinary tract infection. Immunohistochemical analyses showed significantly elevated levels of HSPE1 in tumor cells compared with non-cancerous bladder epithelial cells, suggesting that HSPE1 could be a useful tumor tissue marker for the specific detection of bladder cancer. Collectively, our findings provide valuable information for future validation of potential biomarkers for bladder cancer diagnosis.

Citing Articles

Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).

Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W Int J Oncol. 2025; 66(3).

PMID: 39917986 PMC: 11837902. DOI: 10.3892/ijo.2025.5724.

HSPE1 Inhibits Bladder Cancer Ferroptosis via a Glutathione-Dependent Mechanism by Suppressing GPX4.

Cheng J, Wang L, Wang W, Liang H, Shan S, Zhang S Am J Mens Health. 2024; 18(6):15579883241306904.

PMID: 39688244 PMC: 11653450. DOI: 10.1177/15579883241306904.

Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.

Tabaei S, Haghshenas M, Ariafar A, Gilany K, Stensballe A, Farjadian S Clin Proteomics. 2023; 20(1):28.

PMID: 37501157 PMC: 10373361. DOI: 10.1186/s12014-023-09419-8.

Development of novel gene signatures for the risk stratification of prognosis and diagnostic prediction of osteosarcoma patients using bioinformatics analysis.

Li G, Huang B, Wu H, Zhang H Transl Cancer Res. 2022; 11(7):2374-2387.

PMID: 35966307 PMC: 9372256. DOI: 10.21037/tcr-22-1706.

Prostate cancer detection: a systematic review of urinary biosensors.

Chan K, Gleadle J, OCallaghan M, Vasilev K, MacGregor M Prostate Cancer Prostatic Dis. 2022; 25(1):39-46.

PMID: 34997229 DOI: 10.1038/s41391-021-00480-8.

References

Cappello F . HSP60 and HSP10 as diagnostic and prognostic tools in the management of exocervical carcinoma. Gynecol Oncol. 2003; 91(3):661. DOI: 10.1016/j.ygyno.2003.08.009. View

Huber S, Schwentner C, Taeger D, Pesch B, Nasterlack M, Leng G . Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. 2012; 110(5):699-708. DOI: 10.1111/j.1464-410X.2011.10883.x. View

Lee H, Choi S, Ro J . Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers. Oncol Lett. 2012; 3(3):507-512. PMC: 3362422. DOI: 10.3892/ol.2011.522. View

Jamshidian H, Kor K, Djalali M . Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Urol J. 2008; 5(4):243-7. View

Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F . Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol. 1999; 35(1):52-6. DOI: 10.1159/000019819. View

Rifai N, Gillette M, Carr S . Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006; 24(8):971-83. DOI: 10.1038/nbt1235. View

Frantzi M, van Kessel K, Zwarthoff E, Marquez M, Rava M, Malats N . Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clin Cancer Res. 2016; 22(16):4077-86. DOI: 10.1158/1078-0432.CCR-15-2715. View

Unwin R, Griffiths J, Leverentz M, Grallert A, Hagan I, Whetton A . Multiple reaction monitoring to identify sites of protein phosphorylation with high sensitivity. Mol Cell Proteomics. 2005; 4(8):1134-44. DOI: 10.1074/mcp.M500113-MCP200. View

Saad A, Hanbury D, McNicholas T, Boustead G, Morgan S, Woodman A . A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 2002; 89(4):369-73. DOI: 10.1046/j.1464-4096.2001.01699.x. View

10.

McClellan A, Tam S, Kaganovich D, Frydman J . Protein quality control: chaperones culling corrupt conformations. Nat Cell Biol. 2005; 7(8):736-41. DOI: 10.1038/ncb0805-736. View

11.

Ghaffari Laleh V, Ghaffari Laleh R, Pirany N, Moghadaszadeh Ahrabi M . Measurement of EPF for detection of cow pregnancy using rosette inhibition test. Theriogenology. 2008; 70(1):105-7. DOI: 10.1016/j.theriogenology.2008.02.003. View

12.

Theodorescu D, Wittke S, Ross M, Walden M, Conaway M, Just I . Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7(3):230-40. DOI: 10.1016/S1470-2045(06)70584-8. View

13.

Grossman H, Messing E, Soloway M, Tomera K, Katz G, Berger Y . Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005; 293(7):810-6. DOI: 10.1001/jama.293.7.810. View

14.

Bendtsen J, Kiemer L, Fausboll A, Brunak S . Non-classical protein secretion in bacteria. BMC Microbiol. 2005; 5:58. PMC: 1266369. DOI: 10.1186/1471-2180-5-58. View

15.

Getzenberg R, Konety B, Oeler T, Quigley M, Hakam A, Becich M . Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996; 56(7):1690-4. View

16.

Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M . Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 1998; 4(10):2511-20. View

17.

Syrigos K, Harrington K, Karayiannakis A, Sekara E, Chatziyianni E, Syrigou E . Clinical significance of heat shock protein-70 expression in bladder cancer. Urology. 2003; 61(3):677-80. DOI: 10.1016/s0090-4295(02)02289-6. View

18.

Bendtsen J, Jensen L, Blom N, von Heijne G, Brunak S . Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel. 2004; 17(4):349-56. DOI: 10.1093/protein/gzh037. View

19.

Surinova S, Schiess R, Huttenhain R, Cerciello F, Wollscheid B, Aebersold R . On the development of plasma protein biomarkers. J Proteome Res. 2010; 10(1):5-16. DOI: 10.1021/pr1008515. View

20.

Miyake M, Goodison S, Rizwani W, Ross S, Bart Grossman H, Rosser C . Urinary BTA: indicator of bladder cancer or of hematuria. World J Urol. 2012; 30(6):869-73. PMC: 3537326. DOI: 10.1007/s00345-012-0935-9. View